{"id":3952,"date":"2021-02-02T14:28:36","date_gmt":"2021-02-02T14:28:36","guid":{"rendered":"https:\/\/curell.com\/?p=3952"},"modified":"2022-10-19T20:59:34","modified_gmt":"2022-10-19T20:59:34","slug":"covid-19-vs-propietat-industrial-un-dilema-internacional","status":"publish","type":"post","link":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/","title":{"rendered":"COVID-19 vs propietat industrial, un dilema internacional"},"content":{"rendered":"<div class=\"single-blog-content entry wpex-mt-20 wpex-mb-40 wpex-clr\">\n<p>El passat 2 d\u2019octubre de 2020, l\u2019\u00cdndia i Sud-\u00e0frica van sol\u00b7licitar a l\u2019Organitzaci\u00f3 Mundial del Comer\u00e7 (OMC) que se suspenguessin els drets de patent a nivell internacional per a tots aquells medicaments, vacunes, tractaments o diagn\u00f2stics dirigits a tractar el COVID-19, fins que s\u2019aconsegueixi la immunitat de grup mundial, que l\u2019Organitzaci\u00f3 Mundial de la Salut (OMS) calcula en el 70% de la poblaci\u00f3 del planeta. La iniciativa que dirigeixen l\u2019\u00cdndia i Sud-\u00e0frica ja compta amb el suport d\u2019un centenar de pa\u00efsos, per\u00f2 en canvi topa amb la negativa d\u2019altres, entre els quals es troben els Estats Units i la Uni\u00f3 Europea com a ens supranacional.<\/p>\n<p>La petici\u00f3 de suspendre els drets de patent de manera temporal per a tots aquells medicaments, vacunes, tractaments i diagn\u00f2stics dirigits a tractar el COVID-19 permetria que fabricants de productes gen\u00e8rics produ\u00efssin les vacunes, f\u00e0rmacs o test de COVID-19 que es necessiten per a contenir i posar fi a la pand\u00e8mia a preus netament inferiors als establerts per les companyies que tenen drets de propietat industrial sobre ells. Aix\u00ed, l\u2019objectiu principal de la proposta plantejada \u00e9s que els pa\u00efsos amb menys recursos econ\u00f2mics tamb\u00e9 puguin adquirir i accedir a les cures d\u2019aquest virus que s\u2019ha est\u00e8s per tot el globus.<\/p>\n<p>Per la seva banda, els pa\u00efsos que es postulen en contra de la petici\u00f3 liderada per l\u2019\u00cdndia i Sud-\u00e0frica arg\u00fceixen que ja s\u2019ha creat un mecanisme per a permetre que els f\u00e0rmacs i vacunes que combaten el COVID-19 arribin a tothom, l\u2019Accelerador ACT, que \u00e9s una iniciativa de col\u00b7laboraci\u00f3 mundial per a accelerar el desenvolupament i la producci\u00f3 de proves, tractaments i vacunes contra el COVID-19 i garantir l\u2019acc\u00e9s equitatiu a ells. De l\u2019Accelerador ACT destaca la iniciativa COVAX, l\u2019objectiu de la qual \u00e9s garantir l\u2019acc\u00e9s equitatiu a les vacunes que s\u2019aconsegueixin desenvolupar contra el COVID-19. Aix\u00ed, es pret\u00e9n proveir als 187 socis amb 2.000 milions de vacunes el 2021, tamb\u00e9 als 92 pa\u00efsos de renda baixa i mitjana que no es poden permetre adquirir-les.<\/p>\n<p>No obstant, els actors internacionals que promouen la suspensi\u00f3 de drets de patent citats consideren que l\u2019Accelerador ACT, i concretament la iniciativa COVAX, si b\u00e9 s\u00f3n bones eines per a frenar i\/o eliminar la propagaci\u00f3 del COVID-19 a escala mundial, no s\u00f3n prou r\u00e0pides en relaci\u00f3 amb la velocitat de propagaci\u00f3 i mortalitat del virus, per la qual cosa es requereixen mesures m\u00e9s contundents. En aquest sentit, reclamen que es segueixi, com a m\u00ednim, un cam\u00ed similar al que es va seguir amb el virus VIH\/SIDA fa 20 anys.<\/p>\n<p>L\u2019any 2001 els governs Membres de l\u2019OMC van adoptar per consens la Declaraci\u00f3 relativa a l\u2019Acord sobre els ADPIC i la Salut P\u00fablica en la Quarta Confer\u00e8ncia Ministerial de l\u2019OMC, celebrada a Doha (Qatar). El seu objectiu era respondre a les preocupacions manifestades per diferents Estats i grups de defensa d\u2019interessos p\u00fablics, com l\u2019\u00cdndia o Sud-\u00e0frica, davant la possibilitat que l\u2019Acord sobre els ADPIC dificult\u00e9s als pacients de pa\u00efsos pobres l\u2019obtenci\u00f3 d\u2019alguns medicaments. Aix\u00ed, els actors internacionals volien saber si la flexibilitat prevista en l\u2019Acord sobre els ADPIC era suficient per a garantir el suport de l\u2019Acord a la salut p\u00fablica, especialment per a promoure l\u2019acc\u00e9s en condicions assequibles als medicaments existents i al mateix temps fomentar la recerca i el desenvolupament de nous medicaments.<\/p>\n<p>La Declaraci\u00f3 va respondre a aquestes inquietuds, aclarint diversos aspectes importants de la flexibilitat prevista en l\u2019Acord sobre els ADPIC. Pel que fa a la concessi\u00f3 de llic\u00e8ncies obligat\u00f2ries, la Declaraci\u00f3 estableix amb claredat que tot Membre \u00e9s lliure de determinar les bases sobre les quals es concedeixen aquestes llic\u00e8ncies. L\u2019Acord sobre els ADPIC fa refer\u00e8ncia a diferents motius pels quals es poden concedir llic\u00e8ncies obligat\u00f2ries, entre els quals es troben les emerg\u00e8ncies nacionals i altres circumst\u00e0ncies d\u2019extrema urg\u00e8ncia. La Declaraci\u00f3 indica que cada Membre t\u00e9 el dret de determinar el que constitueix una emerg\u00e8ncia nacional o altres circumst\u00e0ncies d\u2019extrema urg\u00e8ncia, i que les crisis que afecten la salut p\u00fablica, com el VIH\/SIDA, la tuberculosi, el paludisme i altres epid\u00e8mies, poden considerar-se situacions d\u2019aquesta naturalesa.<\/p>\n<p>Arran de la Declaraci\u00f3 de Doha, diferents pa\u00efsos, com l\u2019\u00cdndia o Sud-\u00e0frica, van fer \u00fas de les llic\u00e8ncies obligat\u00f2ries i van comen\u00e7ar a produir gen\u00e8rics de medicines protegides per drets de patent per a tractar, entre altres malalties, el VIH\/SIDA, la qual cosa va permetre que els tractaments fossin molt m\u00e9s econ\u00f2mics i accessibles al p\u00fablic.<\/p>\n<p>No obstant aix\u00f2, la Declaraci\u00f3 de Doha no va implicar que es creessin noves mesures de flexibilitzaci\u00f3 de drets de propietat industrial, sin\u00f3 que va reafirmar les ja existents a l\u2019Acord sobre els ADPIC. En resum, la Declaraci\u00f3 de Doha responia a la pregunta de si una crisi que afecta la salut p\u00fablica, com el virus del VIH\/SIDA, podia ser considerada una emerg\u00e8ncia nacional. Per tant, seguir el mateix cam\u00ed que el de la Declaraci\u00f3 de Doha suposaria que els Membres de l\u2019OMC decidissin per consens que el virus COVID-19 \u00e9s una emerg\u00e8ncia nacional, i en conseq\u00fc\u00e8ncia, que sobre la base del mateix es poguessin concedir llic\u00e8ncies obligat\u00f2ries. Triar aquest cam\u00ed seria allunyar-se de la petici\u00f3 inicial de suspendre els drets de patent a nivell internacional per a tots aquests f\u00e0rmacs, tractaments o vacunes que tracten el COVID-19, de manera que per als actors internacionals liderats per l\u2019\u00cdndia i Sud-\u00e0frica seguir el mateix cam\u00ed que el de la Declaraci\u00f3 de Doha constitueix una mesura subsidi\u00e0ria a la principal, \u00e9s a dir, la suspensi\u00f3 de tots els drets de propietat industrial.<\/p>\n<p>En definitiva, ens trobem davant una situaci\u00f3 molt complicada a nivell internacional, que obliga els Estats membres de l\u2019OMC a prendre decisions de manera cautelosa i tenint en compte tots els factors que entren en joc. A aix\u00f2 responen les nombroses reunions que ha mantingut des del mes d\u2019octubre del 2020 el Consell dels ADPIC per a decidir si se suspenen els drets de patent a nivell internacional per a tots aquells medicaments, vacunes, tractaments o diagn\u00f2stics dirigits a tractar el COVID-19, si emeten una nova Declaraci\u00f3 en la qual decreten que el COVID-19 \u00e9s una emerg\u00e8ncia nacional o internacional, o si simplement mantenen la situaci\u00f3 tal com est\u00e0 ara mateix. No hi ha dubte que es tracta d\u2019un assumpte que crida la nostra atenci\u00f3 i la de tots els actors relacionats amb la propietat industrial i, com no, amb la salut mundial. Ens mantindrem atents a l\u2019evoluci\u00f3 d\u2019aquest tema.<\/p>\n<p>Article d\u2019Albert Olea<\/p>\n<\/div>\n<p>Photo by Fusion Medical Animation on Unsplash<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El passat 2 d\u2019octubre de 2020, l\u2019\u00cdndia i Sud-\u00e0frica van sol\u00b7licitar a l\u2019Organitzaci\u00f3 Mundial del Comer\u00e7 (OMC) que se suspenguessin els drets de patent a nivell internacional per a tots aquells medicaments, vacunes, tractaments o diagn\u00f2stics dirigits a tractar el COVID-19, fins que s\u2019aconsegueixi la&#8230;<\/p>\n","protected":false},"author":3,"featured_media":2895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57,58],"tags":[],"class_list":["post-3952","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualitat","category-articles-ca"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol\" \/>\n<meta property=\"og:description\" content=\"El passat 2 d\u2019octubre de 2020, l\u2019\u00cdndia i Sud-\u00e0frica van sol\u00b7licitar a l\u2019Organitzaci\u00f3 Mundial del Comer\u00e7 (OMC) que se suspenguessin els drets de patent a nivell internacional per a tots aquells medicaments, vacunes, tractaments o diagn\u00f2stics dirigits a tractar el COVID-19, fins que s\u2019aconsegueixi la...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\" \/>\n<meta property=\"og:site_name\" content=\"Curell Su\u00f1ol\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-02T14:28:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T20:59:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"clarapirezcurell@gmail.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"clarapirezcurell@gmail.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\"},\"author\":{\"name\":\"clarapirezcurell@gmail.com\",\"@id\":\"https:\/\/curell.com\/#\/schema\/person\/1c94ad2a17e2ed17aa5e510ba304ff87\"},\"headline\":\"COVID-19 vs propietat industrial, un dilema internacional\",\"datePublished\":\"2021-02-02T14:28:36+00:00\",\"dateModified\":\"2022-10-19T20:59:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\"},\"wordCount\":1184,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/curell.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png\",\"articleSection\":[\"Actualitat\",\"Articles\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\",\"url\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\",\"name\":\"COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol\",\"isPartOf\":{\"@id\":\"https:\/\/curell.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png\",\"datePublished\":\"2021-02-02T14:28:36+00:00\",\"dateModified\":\"2022-10-19T20:59:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage\",\"url\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png\",\"contentUrl\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/curell.com\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19 vs propietat industrial, un dilema internacional\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/curell.com\/#website\",\"url\":\"https:\/\/curell.com\/\",\"name\":\"Curell Su\u00f1ol\",\"description\":\"Patentes, Marcas y Dise\u00f1os desde 1946\",\"publisher\":{\"@id\":\"https:\/\/curell.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/curell.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/curell.com\/#organization\",\"name\":\"Curell Su\u00f1ol\",\"url\":\"https:\/\/curell.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/curell.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/10\/curell-3.png\",\"contentUrl\":\"https:\/\/curell.com\/wp-content\/uploads\/2022\/10\/curell-3.png\",\"width\":300,\"height\":70,\"caption\":\"Curell Su\u00f1ol\"},\"image\":{\"@id\":\"https:\/\/curell.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/es.linkedin.com\/company\/curell-su-ol\",\"https:\/\/www.instagram.com\/curell.sunol\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/curell.com\/#\/schema\/person\/1c94ad2a17e2ed17aa5e510ba304ff87\",\"name\":\"clarapirezcurell@gmail.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/curell.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5ba768f4c1f2dc029882cc058466e728a2fb044efeb07308ce14b58859479d16?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5ba768f4c1f2dc029882cc058466e728a2fb044efeb07308ce14b58859479d16?s=96&d=mm&r=g\",\"caption\":\"clarapirezcurell@gmail.com\"},\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/","og_locale":"ca_ES","og_type":"article","og_title":"COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol","og_description":"El passat 2 d\u2019octubre de 2020, l\u2019\u00cdndia i Sud-\u00e0frica van sol\u00b7licitar a l\u2019Organitzaci\u00f3 Mundial del Comer\u00e7 (OMC) que se suspenguessin els drets de patent a nivell internacional per a tots aquells medicaments, vacunes, tractaments o diagn\u00f2stics dirigits a tractar el COVID-19, fins que s\u2019aconsegueixi la...","og_url":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/","og_site_name":"Curell Su\u00f1ol","article_published_time":"2021-02-02T14:28:36+00:00","article_modified_time":"2022-10-19T20:59:34+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png","type":"image\/png"}],"author":"clarapirezcurell@gmail.com","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"clarapirezcurell@gmail.com","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#article","isPartOf":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/"},"author":{"name":"clarapirezcurell@gmail.com","@id":"https:\/\/curell.com\/#\/schema\/person\/1c94ad2a17e2ed17aa5e510ba304ff87"},"headline":"COVID-19 vs propietat industrial, un dilema internacional","datePublished":"2021-02-02T14:28:36+00:00","dateModified":"2022-10-19T20:59:34+00:00","mainEntityOfPage":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/"},"wordCount":1184,"commentCount":0,"publisher":{"@id":"https:\/\/curell.com\/#organization"},"image":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage"},"thumbnailUrl":"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png","articleSection":["Actualitat","Articles"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/","url":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/","name":"COVID-19 vs propietat industrial, un dilema internacional | Curell Su\u00f1ol","isPartOf":{"@id":"https:\/\/curell.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage"},"image":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage"},"thumbnailUrl":"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png","datePublished":"2021-02-02T14:28:36+00:00","dateModified":"2022-10-19T20:59:34+00:00","breadcrumb":{"@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#primaryimage","url":"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png","contentUrl":"https:\/\/curell.com\/wp-content\/uploads\/2022\/09\/covid-1.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/curell.com\/ca\/covid-19-vs-propietat-industrial-un-dilema-internacional\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/curell.com\/ca\/"},{"@type":"ListItem","position":2,"name":"COVID-19 vs propietat industrial, un dilema internacional"}]},{"@type":"WebSite","@id":"https:\/\/curell.com\/#website","url":"https:\/\/curell.com\/","name":"Curell Su\u00f1ol","description":"Patentes, Marcas y Dise\u00f1os desde 1946","publisher":{"@id":"https:\/\/curell.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/curell.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/curell.com\/#organization","name":"Curell Su\u00f1ol","url":"https:\/\/curell.com\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/curell.com\/#\/schema\/logo\/image\/","url":"https:\/\/curell.com\/wp-content\/uploads\/2022\/10\/curell-3.png","contentUrl":"https:\/\/curell.com\/wp-content\/uploads\/2022\/10\/curell-3.png","width":300,"height":70,"caption":"Curell Su\u00f1ol"},"image":{"@id":"https:\/\/curell.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/es.linkedin.com\/company\/curell-su-ol","https:\/\/www.instagram.com\/curell.sunol\/"]},{"@type":"Person","@id":"https:\/\/curell.com\/#\/schema\/person\/1c94ad2a17e2ed17aa5e510ba304ff87","name":"clarapirezcurell@gmail.com","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/curell.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5ba768f4c1f2dc029882cc058466e728a2fb044efeb07308ce14b58859479d16?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5ba768f4c1f2dc029882cc058466e728a2fb044efeb07308ce14b58859479d16?s=96&d=mm&r=g","caption":"clarapirezcurell@gmail.com"},"url":"#"}]}},"_links":{"self":[{"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/posts\/3952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/comments?post=3952"}],"version-history":[{"count":1,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/posts\/3952\/revisions"}],"predecessor-version":[{"id":3953,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/posts\/3952\/revisions\/3953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/media\/2895"}],"wp:attachment":[{"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/media?parent=3952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/categories?post=3952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/curell.com\/ca\/wp-json\/wp\/v2\/tags?post=3952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}